Yesokay
380 posts

Yesokay
@Midwitmidwit
Boring, self-deprecatating science educator moonlighting as a situation monitor.




Unpopular Opinion: Tirzepatide is a better choice for most people than Retatrutide. TRIUMPH-1 trial results prove it: Reta 4 mg: 19% weight loss at 80 weeks Tirz 10 mg: 19.5% weight loss at 72 weeks Reta is only superior at 9+ mg doses (25.9%) with far more side effects:

The Trump slush fund is a clear cut impeachable offense. #nt=0000016a-0e43-dffa-a76b-3f6bfa3f0002-showMedia-liI0promoMedium-contentFooter" target="_blank" rel="nofollow noopener">latimes.com/opinion/story/…




Eli Lilly released retatrutide Phase 3 data yesterday. 28% weight loss in 80 weeks. The most powerful obesity drug that’s ever been tested. And today the cancer signal drops. 12,112 patients. Seven tumor types. GLP-1 users had half the lung cancer metastasis rate (10% vs 22%). Breast cancer: 43% cut. Colon cancer five-year mortality in a separate study: 15.5% vs 37.1%. Cancer joins a list that already includes heart disease (SELECT, 20% MACE reduction), kidney failure (FLOW, 24% slower decline), sleep apnea (SURMOUNT-OSA, FDA-approved), addiction (BMJ, 600K veterans, 18-25% reduction across substances), and liver disease (86% fat clearance). Tumors express GLP-1 receptors. Activate them and NF-kB drops, apoptosis rises. The drug isn’t just shrinking fat. It’s talking directly to the cancer. One drug class. Designed for blood sugar. The biology keeps finding uses the designers didn’t predict.




Now that we have phase-3 results for retatrutide, it's time to revisit the question: What would happen to obesity if we gave every obese (BMI 30+) person the drug for just one year? Well, the obesity rate would fall by more than 80%! We'd be skinnier than the U.S. circa 1980!

A new study has found that nearly 1.2 billion people worldwide had mental disorders in 2023, reflecting a 95.5% increase since 1990, with the largest increases in anxiety and depression. cnn.it/4a5hKDV















